![Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41746-021-00470-z/MediaObjects/41746_2021_470_Fig4_HTML.png)
Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine
EIT Health - Ioannis Tarnanas is the winner of #EIT Innovators Award. He is CSO for Altoida- makers of ADPS, which can tell if someone will develop Alzheimer's disease within 6 years,
![Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases | TechCrunch Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases | TechCrunch](https://techcrunch.com/wp-content/uploads/2019/05/Screen-Shot-2019-05-29-at-7.31.52-PM.png)
Using augmented reality, Altoida is identifying the likely onset of neurodegenerative diseases | TechCrunch
EIT Health - Congratulations to Altoida for raising $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality. Altoida CSO – Dr. Ioannis Tarnanas was the
![Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study | npj Digital Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41746-021-00470-z/MediaObjects/41746_2021_470_Fig1_HTML.png)